Pharma Business - September 22, 2025
Sobi’s Tryngolza approved in the EU for familial chylomicronemia syndrome
Sobi and Ionis Pharmaceuticals have announced that Tryngolza (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS).
Pharma Business - September 17, 2025
EU approval of updated label of Novo Nordisk’s oral semaglutide
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.
Agreement - September 17, 2025
ALK enters partnership with GenSci
ALK has announced a partnership agreement with China-based Changchun GeneScience Pharmaceutical to develop and commercialize ALK’s house dust mite allergy immunotherapy (AIT) products in Mainland China.
Pharma Business - September 12, 2025
Lundbeck sharpens its commercial focus
Lundbeck will transition its operations to a partnership model in 27 markets in Europe and International Operations through new partnerships with Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals.
Financing - September 3, 2025
ProTest Diagnostics receives Wada grant
The company has secured a significant grant from the World Anti-Doping Agency (WADA) to develop technology aimed at detecting blood doping.
Biotech Business - August 29, 2025
Modus Therapeutics raises approximately SEK 28.3 million
The net proceeds of approximately SEK 24.4 million, of which approximately SEK 5 million refers to set-off against outstanding loans from Modus’ largest shareholder Karolinska Development, and after transaction costs of approximately SEK 3.9 million, will primarily be used to finance clinical activities, including the ongoing phase II study, states the company.
